US FDA’s ARIA Analysis Adds Earlier Scan To Biogen/Eisai Leqembi Label

 
• By Bridget Silverman
  
The US FDA added a fourth MRI scan to labeling for Biogen/Eisai's Leqembi to help identify patients with ARIA-E adverse events early. (Shutterstock)

More from Drug Safety

More from United States